Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ENOV | Common stock, par value $.001 | -Sell | -$68,711 | -1,629 | -1.98% | $42.18 | 80,818 | Feb 25, 2022 | Direct | F1 |
transaction | ENOV | Common stock, par value $.001 | +Grant/Award | $0 | +44,145 | +54.62% | $0.00 | 124,963 | Feb 25, 2022 | Direct | F2 |
transaction | ENOV | Common stock, par value $.001 | -Sell | -$874,511 | -21,190 | -16.96% | $41.27 | 103,773 | Feb 28, 2022 | Direct | F1 |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to meet tax obligations relating to the vesting and delivery of certain restricted stock units and performance-based restricted stock units ("PRSUs"). |
F2 | Reflects the certification of the performance criteria for PRSUs previously awarded in 2019. For more details on the PRSUs, please refer to the "Outstanding Equity Awards at 2020 Fiscal Year-End" table on page 42 of Colfax Corporation's 2021 Proxy Statement as filed with the Securities and Exchange Commission on April 1, 2021. |